Genus helps farmers to produce high-quality meat and milk more efficiently and sustainably, we do this by continuously producing superior breeding animals through genetic improvement, with characteristics tailed for different markets.


Strategic Priorities

We invest in the latest technology to continuously improve our own herds and product offering, and we protect our unique position by choosing how to deploy our genes and technology in the marketplace.

What does success look like?

Genetic Gain

Creating better breeding animals for farmers, measured against proprietary and public indices which are weighted towards economic traits that help farmers operate more efficiently and sustainably.


Measures the genetic improvement we achieve in our porcine nucleus herds, which ultimately filters down to our customers’ farms.


US$ profitability, per commercial pig per year, on a rolling three-year average. Prior years’ index ratings have been updated, to reflect the latest results from genomic selection and the economic values of pork production.


Implementing genomic selection technology in 2013 led to a step change in genetic gain value improvement in the following years and has delivered a further improvement of US$3.46 per pig, per year, in 2019.


Monitors how many of our bulls are highly ranked, based on economically relevant traits for farmers.


The number of our generally available Holstein bulls listed in the top 100 Genomic Net Merit US$ rankings for genomically tested sires and the top 100 Net Merit rankings for daughter proven sires.


Genus has established and maintained a leadership position with its strength in genomic bulls, which over time will become daughter proven bulls. This is mainly driven by the growing proportion of high-quality bulls sourced from our proprietary breeding programme, De Novo.*


Strategic priorities

We focus our offering on leading integrated pork producers and progressive cattle farmers worldwide. We offer them our superior breeding animals, semen and embryos, together with technical services, tailored to their needs.

What does success look like?

Volume Growth

Creating better breeding animals for farmers, measured against proprietary and public indices which are weighted towards economic traits that help farmers operate more efficiently and sustainably.


Tracks the growth in the number of commercial pigs with PIC genetics globally.


The change in volume of both direct and royalty animal sales, using a standardised MPEs measure of commercial slaughter animals that contain our genetics.


Volumes were stable at 150 million MPEs. Excluding China, where volumes declined 50% as a result of ASF, all regions contributed to a growth of 5%. Royalty contract volumes increased 7%, fuelled particularly by double digit growth in Latin America and Asia.


Tracks our global unit sales growth in diary and beef.


The change in dairy, beef and sorted units of semen and embryos delivered or produced for customers in the year.


Bovine volumes improved 6% to 19.7 million units, primarily from growth in North America and Latin America. Sexed volumes were up 42%, reflecting strong growth in Sexcel, which also influenced the use of beef-on-dairy genetics, supporting a 22% increase in global beef volumes. Embryo volumes were marginally up as growth was impacted by phasing of production in key accounts.


Sharing in the Value Delivered

strategic priorities

We aim to capture an appropriate share of the value we deliver to customers, aligning our interests with theirs. We demonstrate the value of our genetics on farm through validation trials and data, and link our pricing to genetic indices and our customers’ productivity.

What does success look like?


Generating profit resulting from the performance of our products in customers’ systems.

Operating profit per market equivalent.png

Monitors porcine profitability by unit.


Net porcine adjusted operating profit globally, expressed per MPE. Results include our share of Agroceres PIC, our Brazilian joint venture.


Operating profit per MPE was £0.60, up £0.04 (up £0.03 in constant currency). This was primarily due to strong royalty contract revenue growth more than offsetting lower profits in China.


Bovine operating profit per dose.png

Monitors bovine profitability by dose.


Bovine adjusted operating profit globally, expressed per dose of semen or embryo delivered or produced for customers. Prior years have been restated to include India which had previously been excluded.


Operating profit per dose was £0.50, up £0.02. This was due to the strong sales growth of our premium Sexcel product, which has lower production costs than its predecessor technology, partially offset by increased investment in bovine product development.


* De Novo Genetics LLC is 51% owned by Genus.